Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer

被引:6
作者
Kuroda, Hiroaki [1 ]
Ichinose, Junji [2 ]
Masago, Katsuhiro [3 ]
Takahashi, Yusuke [1 ]
Nakada, Takeo [1 ]
Nakao, Masayuki [2 ]
Okumura, Sakae [2 ]
Hashimoto, Kohei [2 ]
Matsuura, Yosuke [2 ]
Sakakura, Noriaki [1 ]
Matsushita, Hirokazu [4 ]
Mun, Mingyon [2 ]
机构
[1] Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 4648681, Japan
[2] Canc Inst Hosp, Dept Thorac Surg Oncol, Tokyo 1358550, Japan
[3] Aichi Canc Ctr, Dept Pathol & Mol Diagnost, Nagoya, Aichi 4640021, Japan
[4] Aichi Canc Ctr, Div Translat Oncoimmunol, Res Inst, Nagoya, Aichi 4640021, Japan
来源
MEDICINA-LITHUANIA | 2021年 / 57卷 / 12期
关键词
non-small cell lung cancer; lobe-specific lymph node dissection; systemic lymph node dissection; carcinoembryonic antigen; lobectomy; LONG-TERM SURVIVAL; CLASSIFICATION; SURGERY;
D O I
10.3390/medicina57121365
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives: Lobe-specific nodal dissection (L-SND) is currently acceptable for the dissection of early-stage non-small cell lung cancer (NSCLC) but not for cancers of more advanced clinical stages. We aimed to assess the efficacy of L-SND, compared to systemic nodal dissection (SND). Materials and Methods: We retrospectively collected the clinical data of patients with carcinoembryonic antigen (CEA) abnormality who underwent complete resection of NSCLC via lobectomy or more in addition to either SND or L-SND at two cancer-specific institutions from January 2006 to December 2017. Results: A total of 799 patients, including 265 patients who underwent SND and 534 patients who underwent L-SND, were included. On multivariate analysis, thoracotomy, more than lobectomy, cN1-2, advanced pathological stage, adjuvant treatment, and EGFR or ALK were strongly associated with SND. No significant differences were found in overall survival, disease-free survival, and overtime survival after propensity adjustment (p = 0.09, p = 0.11, and p = 0.50, respectively). There were no significant differences in local (p = 0.16), regional (p = 0.72), or distant (p = 0.39) tumor recurrence between the two groups. Conclusions: SND did not improve the prognosis of NSCLC patients with CEA abnormality. Complete pulmonary resection via L-SND seems useful for NSCLC patients with CEA abnormality.
引用
收藏
页数:11
相关论文
共 26 条
  • [1] Subcarinal lymph node in upper lobe non-small cell lung cancer patients: Is selective lymph node dissection valid?
    Aokage, Keiju
    Yoshida, Junji
    Ishii, Genichiro
    Hishida, Tomoyuki
    Nishimura, Mitsuyo
    Nagai, Kanji
    [J]. LUNG CANCER, 2010, 70 (02) : 163 - 167
  • [2] Adjuvant and Neoadjuvant Immunotherapy in Non - small Cell Lung Cancer
    Broderick, Stephen R.
    [J]. THORACIC SURGERY CLINICS, 2020, 30 (02) : 215 - +
  • [3] European trends in preoperative and intraoperative nodal staging: ESTS guidelines
    De Leyn, P.
    Lardinois, D.
    Van Schil, P.
    Rami-Porta, R.
    Passlick, B.
    Zielinski, M.
    Waller, D.
    Lerut, T.
    Weder, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (04) : 357 - 361
  • [4] Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Aggarwal, Charu
    Aisner, Dara L.
    Akerley, Wallace
    Bauman, Jessica R.
    Bharat, Ankit
    Bruno, Debora S.
    Chang, Joe Y.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dobelbower, Michael
    Gettinger, Scott
    Govindan, Ramaswamy
    Gubens, Matthew A.
    Hennon, Mark
    Horn, Leora
    Lackner, Rudy P.
    Lanuti, Michael
    Leal, Ticiana A.
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato G.
    Otterson, Gregory A.
    Patel, Sandip P.
    Reckamp, Karen L.
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Stevenson, James
    Swanson, Scott J.
    Tauer, Kurt W.
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (12): : 1464 - 1472
  • [5] Is lobe specific lymph node dissection adequate for cN0-1 non-small cell lung cancer?
    Fang, Likui
    Xu, Jinming
    Ye, Bo
    Yu, Guocan
    Chen, Gang
    Yang, Jun
    [J]. JOURNAL OF CARDIOTHORACIC SURGERY, 2020, 15 (01)
  • [6] Validation of the lung cancer staging system revisions using a large prospective clinical trial database (ACOSOG Z0030)
    Fibla, Juan J.
    Cassivi, Stephen D.
    Decker, Paul A.
    Allen, Mark S.
    Darling, Gail E.
    Landreneau, Rodney J.
    McKenna, Robert J.
    Putnam, Joe B.
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2013, 43 (05) : 911 - 914
  • [7] The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
    Goldstraw, Peter
    Chansky, Kari
    Crowley, John
    Rami-Porta, Ramon
    Asamura, Hisao
    Eberhardt, Wilfried E. E.
    Nicholson, Andrew G.
    Groome, Patti
    Mitchell, Alan
    Bolejack, Vanessa
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (01) : 39 - 51
  • [8] The clinicopathological features associated with skip N2 metastases in patients with clinical stage IA non-small-cell lung cancer
    Gorai, Atsuo
    Sakao, Yukinori
    Kuroda, Hiroaki
    Uehara, Hirofumi
    Mun, Mingyon
    Ishikawa, Yuichi
    Nakagawa, Ken
    Masuda, Munetaka
    Okumura, Sakae
    [J]. EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2015, 47 (04) : 653 - 658
  • [9] Prognostic Impact of the Current Japanese Nodal Classification on Outcomes in Resected Non-small Cell Lung Cancer
    Ichinose, Junji
    Murakawa, Tomohiro
    Hino, Haruaki
    Konoeda, Chihiro
    Inoue, Yuta
    Kitano, Kentaro
    Nagayama, Kazuhiro
    Nitadori, Jun-ichi
    Anraku, Masaki
    Nakajima, Jun
    [J]. CHEST, 2014, 146 (03) : 644 - 649
  • [10] Are Lobe-Specific Mediastinal Lymph Node Dissections Reasonable for Peripheral Stage Ia Non-small Cell Lung Cancer?
    Karush, Justin M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (02) : 331 - 332